Author

Stefan Schreiber

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY
SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY

Stefan Schreiber  et al.

ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION

Stefan Schreiber  et al.

ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION
ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION

Stefan Schreiber  et al.

THE ADDITION OF BOWEL URGENCY IMPROVEMENT TO THE ACHIEVEMENT OF CLINICAL RESPONSE AND REMISSION WAS ASSOCIATED WITH BETTER QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS FROM MIRIKIZUMAB PHASE 3 TRIALS
THE ADDITION OF BOWEL URGENCY IMPROVEMENT TO THE ACHIEVEMENT OF CLINICAL RESPONSE AND REMISSION WAS ASSOCIATED WITH BETTER QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS FROM MIRIKIZUMAB PHASE 3 TRIALS

Stefan Schreiber  et al.

THE ADDITION OF BOWEL URGENCY IMPROVEMENT TO THE ACHIEVEMENT OF CLINICAL RESPONSE OR REMISSION WAS ASSOCIATED WITH BETTER WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS FROM MIRIKIZUMAB PHASE 3 TRIALS
THE ADDITION OF BOWEL URGENCY IMPROVEMENT TO THE ACHIEVEMENT OF CLINICAL RESPONSE OR REMISSION WAS ASSOCIATED WITH BETTER WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS FROM MIRIKIZUMAB PHASE 3 TRIALS

Stefan Schreiber  et al.

RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN WPAI SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITI
RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN WPAI SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITI

Stefan Schreiber  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Stefan Schreiber  et al.

RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT OR BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN IBDQ SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT OR BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN IBDQ SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Stefan Schreiber  et al.

MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES
MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Stefan Schreiber  et al.

MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN
MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN

Stefan Schreiber  et al.

IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION
IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION

Stefan Schreiber  et al.

EARLY MOLECULAR SIGNATURES OF THERAPEUTIC RESPONSE TO VEDOLIZUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS IDENTIFIED USING A LONGITUDINAL MULTI-OMICS APPROACH
EARLY MOLECULAR SIGNATURES OF THERAPEUTIC RESPONSE TO VEDOLIZUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS IDENTIFIED USING A LONGITUDINAL MULTI-OMICS APPROACH

Stefan Schreiber  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Stefan Schreiber  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Stefan Schreiber  et al.

IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Stefan Schreiber  et al.

CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POST HOC ANALYSIS OF SELECTION
CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POST HOC ANALYSIS OF SELECTION

Stefan Schreiber  et al.

THE EFFECT OF COMMONLY PRESCRIBED MEDICATIONS ON THE TRANSCRIPTOME OF PATIENTS SUFFERING FROM IBD AND OTHER CHRONIC INFLAMMATORY DISEASES
THE EFFECT OF COMMONLY PRESCRIBED MEDICATIONS ON THE TRANSCRIPTOME OF PATIENTS SUFFERING FROM IBD AND OTHER CHRONIC INFLAMMATORY DISEASES

Stefan Schreiber  et al.

TRYPTOPHAN METABOLITES DYNAMICALLY ASSOCIATE WITH FATIGUE ALLEVIATION IN IBD
TRYPTOPHAN METABOLITES DYNAMICALLY ASSOCIATE WITH FATIGUE ALLEVIATION IN IBD

Stefan Schreiber  et al.

Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)
Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)

Stefan Schreiber  et al.

CHROMOCOLONOSCOPY WITH MICROENCAPSULATED PATENT BLUE V - AN EFFECTIVE OPTION FOR COLONIC MUCOSAL STAINING
CHROMOCOLONOSCOPY WITH MICROENCAPSULATED PATENT BLUE V - AN EFFECTIVE OPTION FOR COLONIC MUCOSAL STAINING

Stefan Schreiber  et al.

Item 41 - 60 / 72
1 2
3
4